Article

Case of anakinra as a steroid-sparing agent for gout inflammation

University of California, San Francisco, CA, USA.
Arthritis & Rheumatology (Impact Factor: 7.76). 09/2009; 61(9):1268-70. DOI: 10.1002/art.24694
Source: PubMed
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Speech recognizers trained in one condition but operating in a different condition degrade in performance. Typical of this situation is when the recognizer is trained under normal conditions but operated in a stressful and noisy environment as in military applications. This paper reports on recognition experiments conducted with a "simulated stress" data base using a baseline algorithm and its modifications. These algorithms perform acceptably well (1 % substitution rate) for a vocabulary of 105 words under normal conditions, but degrade by an order of magnitude under the "stress" conditions. The experiments also show that the speech production variation caused by noise exposure at the ear is far more deleterious than ambient acoustic noise with a noise cancelling microphone.
    Preview · Conference Paper · May 1986
  • Source

    Full-text · Article · May 2007 · Value in Health
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The clinical successes of targeting angiogenesis provide a basis for trials of interleukin-1 (IL-1) blockade and particularly anti-IL-1beta as an add-on therapy in human metastatic disease. In animal studies for over 20 years, IL-1 has been demonstrated to increase adherence of tumor cells to the endothelium in vitro, and administration of IL-1 to mice increases the number of metastatic colonies and tumor growth. Importantly, reducing endogenous IL-1 activity, particularly IL-1beta, with the naturally occurring IL-1 receptor antagonist (IL-1Ra) reduces both metastasis as well as tumor burden. Inhibition of IL-1 activity prevents in vivo blood vessel formation induced by products released from hypoxic macrophages or vascular endothelial cell growth factor itself. Mice deficient in IL-1beta do not form blood vessels in matrigels embedded with vascular endothelial cell growth factor or containing products of macrophages. Recombinant IL-1Ra (anakinra) has been administered to over 1,000 patients with septic shock resulting in a consistent reduction in all-cause 28-day mortality. Approved for treatment of rheumatoid arthritis, anakinra has a remarkable safety record. Anakinra resulted in decreased blood vessels in the pannus of affected joints in patients with rheumatoid arthritis. Neutralizing monoclonal antibodies to IL-1beta and a soluble receptor to IL-1 are approved for treating chronic inflammatory diseases. Given the availability of three therapeutic agents for limiting IL-1 activity, the safety of blocking IL-1, and the clear benefit of blocking IL-1 activity in animal models of metastasis and angiogenesis, clinical trials of IL-1 blockade should be initiated, particularly as an add-on therapy of patients receiving antiangiogenesis-based therapies.
    Full-text · Article · Jun 2010 · CANCER AND METASTASIS REVIEW
Show more